The potential mechanisms of Aβ-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer's disease

International Journal of Neuroscience

Volumn 124, Issue 2, 2014, Pages 75-81

  Wan, Wenbin ^a   Chen, Huixian ^a   Li, Yaming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

amyloid; Alzheimer's disease; Blood brain barrier; Receptor for advanced glycation end products; Tight junctions

Indexed keywords

ACTIN; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; CALCINEURIN; CALCIUM ION; CLAUDIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; OCCLUDIN; PROTEIN S 100; REACTIVE OXYGEN METABOLITE; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CELL JUNCTION; CELL SURFACE; COGNITION; CYTOTOXICITY; ELECTROMAGNETIC FIELD; GLIA CELL; HUMAN; MICROVASCULAR ENDOTHELIAL CELL; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PERICYTE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TIGHT JUNCTION; TRANSCYTOSIS; ENDOTHELIUM CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TOXICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BLOOD-BRAIN BARRIER; ENDOTHELIAL CELLS; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MOLECULAR TARGETED THERAPY; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TIGHT JUNCTIONS;

EID: 84892391503     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.825258     Document Type: Article

References (60)

1. Lomoio S, Lopez-Gonzalez I, Aso E, et al. Cerebellar amyloidbeta plaques: Disturbed cortical circuitry in AbetaPP/PS1 transgenic mice as a model of familial Alzheimer's disease. J Alzheimer's disease: JAD 2012;31:285-300
2. Biron KE, Dickstein DL, Gopaul R, JefferiesWA. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PloS One 2011;6:e23789
3. Love S, Miners S, Palmer J, et al. Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Front Biosci 2009;14:4778-92
4. Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer's disease: Progress, problems and perspectives. Drug Discov Today 2006;11:931-8
5. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS & Neurol Disord Drug Targets 2009;8:16-30
6. Sharma HS, Castellani RJ, Smith MA, Sharma A. The bloodbrain barrier in Alzheimer's disease: Novel therapeutic targets and nanodrug delivery. Int Rev Neurobiol 2012;102:47-90
7. Shen S, Zhang W. ABC transporters and drug efflux at the blood-brain barrier. Rev Neurosci 2010;21:29-53
8. Ronaldson PT, Davis TP. Blood-brain barrier integrity and glial support: Mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr Pharm Des 2012;18:3624-44
9. Correale J, Villa A. Cellular elements of the blood-brain barrier. Neurochem Res 2009;34:2067-77
10. Coisne C, Engelhardt B. Tight junctions in brain barriers during central nervous system inflammation. Antioxid Redox Signal 2011;15:1285-303
11. Luissint AC, Artus C, Glacial F, et al. Tight junctions at the blood brain barrier: Physiological architecture and diseaseassociated dysregulation. Fluids Barriers CNS 2012;9:23
12. Baeten KM, Akassoglou K. Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. Dev Neurobiol 2011;71:1018-39
13. Bednarczyk J, Lukasiuk K. Tight junctions in neurological diseases. Acta Neurobiol Exp (Wars) 2011;71:393-408
14. Liu WY, Wang ZB, Zhang LC, et al. Tight junction in bloodbrain barrier: An overview of structure, regulation, and regulator substances. CNS Neurosci Ther 2012;18:609-15
15. Zlokovic BV.The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178-201
16. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005;28:202-8
17. Marchesi VT. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: Implications for early detection and therapy. FASEB J 2011;25:5-13
18. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev. Neurosci 2011;12:723-38
19. Han BH, Zhou ML, Abousaleh F, et al. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: Contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci 2008;28:13542-50
20. Tai LM, Holloway KA, Male DK, et al. Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 2010;14:1101-12
21. Carrano A, Hoozemans JJ, van der Vies SM, et al. Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 2011;15:1167-78
22. Hartz AM, Bauer B, Soldner EL, et al. Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 2012;43:514-23
23. Crehan H, Hardy J, Pocock J. Microglia, Alzheimer's disease, and complement. Int J Alzheimer's Dis 2012;2012:983 640
24. Miners JS, Barua N, Kehoe PG, et al. Abeta-degrading enzymes: Potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 2011;70:944-59
25. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 2004;89:807-11
26. Wilhelmus MM, Otte-Holler I, van Triel JJ, et al. Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol 2007;171:1989-99
27. Deane R, Singh I, Sagare AP, et al. A multimodal RAGEspecific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012;122:1377-92
28. RJ D. Is RAGE still a therapeutic target for Alzheimer's disease? Future Med Chem 2012;4:915-25
29. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907-13
30. Slowik A, Merres J, Elfgen A, et al. Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)-And amyloid beta1-42-induced signal transduction in glial cells. Mol Neurodegeneration 2012;7:55
31. Yin QQ, Dong CF, Dong SQ, et al. AGEs induce cell death via oxidative and endoplasmic reticulum stresses in both human SH-SY5Y neuroblastoma cells and rat cortical neurons. Cell Mol Neurobiol 2012;32:1299-309
32. Ohtsuki S, Ito S, Terasaki T. Is P-glycoprotein involved in amyloid-beta elimination across the blood-brain barrier in Alzheimer's disease? Clin Pharmacol Ther 2010;88: 443-5
33. Abuznait AH, Kaddoumi A. Role of ABC transporters in the pathogenesis of Alzheimer's disease. ACS Chem Neurosci 2012;3:820-31
34. Fritz G. RAGE: A single receptor fits multiple ligands. Trends Biochem Sci 2011;36:625-32
35. Lue LF, Walker DG, Brachova L, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: Identification of a cellular activation mechanism. Exp Neurol 2001;171:29-45
36. Origlia N, Arancio O, Domenici L, Yan SS. MAPK, betaamyloid and synaptic dysfunction: The role of RAGE. Expert Rev Neurotherapeutics 2009;9:1635-45
37. Maczurek A, Shanmugam K, Munch G. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. Ann N Y Acad Sci 2008;1126: 147-51
38. Arancio O, Zhang HP, Chen X, et al. RAGE potentiates Abetainduced perturbation of neuronal function in transgenic mice. EMBO J 2004;23:4096-105
39. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-Amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008;28:8354-60
40. Hu Q, Chen C, Yan J, et al. Therapeutic application of gene silencing MMP-9 in a middle cerebral artery occlusion-induced focal ischemia rat model. Exp Neurol 2009;216:35-46
41. Cruzalegui FH, Bading H. Calcium-regulated protein kinase cascades and their transcription factor targets. Cell Mol Life Sci 2000;57:402-10
42. Yang Y, Hill JW, Rosenberg GA. Multiple roles of metalloproteinases in neurological disorders. Progress in Mol Biol Translational Sci 2011;99:241-63
43. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of bloodbrain barrier and white matter components after cerebral ischemia. J Neurosci 2001;21:7724-32
44. Yang Y, Rosenberg GA. MMP-mediated disruption of claudin-5 in the blood-brain barrier of rat brain after cerebral ischemia. Methods Mol Biol 2011;762:333-45
45. Zhang YM, Zhou Y, Qiu LB, et al. Altered expression of matrix metalloproteinases and tight junction proteins in rats following PEMF-induced BBB permeability change. Biomed Environ Sci: BES 2012;25:197-202
46. Du H, Li P, Wang J, et al. The interaction of amyloid beta and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. Cell Mol Neurobiol 2012;32:141-7
47. Zhu P, Ren M, Yang C, et al. Involvement of RAGE, MAPK and NF-kappaB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol 2012;21:123-9
48. Chen D, Wei XT, Guan JH, et al. Inhibition of c-Jun N-Terminal kinase prevents blood-brain barrier disruption and normalizes the expression of tight junction proteins clautin-5 and ZO-1 in a rat model of subarachnoid hemorrhage. Acta Neurochir 2012;154:1469-76; discussion 76
49. Zhang L, Jouret F, Rinehart J, et al. AMP-Activated protein kinase (AMPK) activation and glycogen synthase kinase-3beta (GSK-3beta) inhibition induce Ca2+-independent deposition of tight junction components at the plasma membrane. J Biol Chem 2011;286:16879-90
50. Fujita H, Sugimoto K, Inatomi S, et al. Tight junction proteins claudin-2 and-12 are critical for vitamin Ddependent Ca2+absorption between enterocytes.Mol Biol Cell 2008;19:1912-21
51. Kagan BL, Hirakura Y, Azimov R, et al. The channel hypothesis of Alzheimer's disease: Current status. Peptides 2002;23:1311-5
52. Kook SY, Hong HS, Moon M, et al. Abeta(1)(-)(4)(2)-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca(2)(+)-calcineurin signaling. J Neurosci 2012;32: 8845-54
53. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Current drug targets. CNS Neurol Disord 2005;4:249-66
54. Perrone L, Sbai O, Nawroth PP, Bierhaus A. The complexity of sporadic Alzheimer's disease pathogenesis: The role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction. Int J Alzheimer's Dis 2012;2012:734956
55. Pfizer, Alzheimer's Disease Cooperative Study (ADCS). A phase 2 study evaluating the efficacy and safety of PF 04494700 in mild to moderate Alzheimer's disease. Clinical Trails. gov Identifier: NCT00566397. 2007-2010. Available at: Http://clinicaltrials.gov/ct2/show/NCT00566397
56. Sabbagh MN, Agro A, Bell J, et al. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:206-12
57. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: Therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010;79:1379-86
58. Han SH, Kim YH, Mook-Jung I. RAGE: The beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011;31:91-7
59. Yan FL, Zheng Y, Zhao FD. Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia. Acta Neuropathol 2008;116:529-35
60. AHAF (2011): The Facts on Alzheimer's Disease. 2011 01/11/11 [cited2011 03/07/11]. Available at: Http://www.ahaf. org/alzheimers/about/understanding/ facts.html. Last accessed 7 March 2011